TPN171H
As of the edition of 20 October 2026, TPN171H is a drug known only by a code name: in active development; acts on PDE5A.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2021
- Kind
- Code name only
- Registered trials
- 14, 0 stopped early
- Disease areas
- Mental health; Urinary and reproductive; Lungs and airways; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PDE5A | cGMP-specific 3',5'-cyclic phosphodiesterase | O76074 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 9 | 9 | 0 | 0 |
| Phase 2 | 3 | 3 | 0 | 0 |
| Phase 3 | 2 | 2 | 0 | 0 |
| All trials | 14 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Vigonvita Life Sciences | Lead sponsor of trials | 2019 to now |